Our Latest Stories
Our Science
June 19, 2025
Digital and AI Powered Manufacturing & Supply: Delivering Faster and Safer for Patients
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Our Pipeline
5
Therapeutic areas
86
Compounds in clinical development
24
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
June 30, 2025
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
June 25, 2025
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
June 23, 2025
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma